Bayer Aktiengesellschaft

Bayer Healthcare Aktiengesellschaft

Lanxess Deutschland Gmbh

Bayer Schering Pharma Ag

Bayer Pharmaceuticals Corporation

Bayer Aktiengellschaft

Paul Naab

Markus Heil

Dietmar Flubacher

Johannes-Peter Stasch

Frank Wunder

Klaus Dembowsky

Elke Stahl

Cristina Alonso-Alija

Delf Schmidt

Gunter Schmidt

Elisabeth Perzborn

Hilmar Bischoff

Carsten Schmeck

Klaus-Dieter Bremm

Josef Pernerstorfer

Arndt Brandes

Holger Paulsen

Jan-Bernd Lenfers

Karl G Metzger

Arnd Voerste

Karl-Heinz Schlemmer

Peter Fey

Joachim Schuhmacher

Rolf Angerbauer

Ulrich Rosentreter

Klemens Lustig

Dirk Denzer

Dieter Habich

Heinrich Meier

Michael Preiss

Jean-Marie-Viktor De Vry

Marcus Bauser

Frank Mauler

Nils Burkhardt

Michael Boberg

Jens-Kerim Ergüden

Henry Giera

Rudolf Zerbes

J&uuml;rgen Stoltefuss

Kai Van Laak

Maria Niewöhner

Michael L&ouml;gers

Michael Conrad

Samir Samaan

Jürgen Stoltefuss

Elizabeth Perzborn

Volker Hinz

Joachim Lanz

Werner Teller

Arthur Haaf

Andreas Knorr

Hans-Joachim Zeiler

Rudolf Schohe-Loop

Jurgen Stoltefuss

Adrian Tersteegen

Thomas Lampe

Jörg Keldenich

Martin Hendrix

Matthias Muller-Gliemann

Wilfried Schrock

Gerhard Franckowiak

Stefan Antons

Claudia Hirth-Dietrich

Olaf Weber

Herbert Diehl

Stephen Boyer

Guido Giffels

Arno Friedl

Reinhard Jork

Florian Rampf

Matthias Gotta

Christiane Faeste

Dagmar Schauss

Wolfgang Koebernick

Irene Gerlach

Michael Schauer

Björn Schlummer

Ulrich Schorsch

Elmar Reinhold Burchardt

David Brückner

Stephan Nicholas M&uuml;ller

Thorsten Oliver Repp

Thorsten-Oliver Repp

Willi Lange

Andrea Sewing

Mark Miglarese

Swen Allerheiligen

Matthias M&uuml;ller-Gliemann

The invention relates to compounds of formulae (II), (IV), and (VI) as shown below, wherein the several variable groups are as defined in the specification and claims. Processes for making these materials, and methods for using them in the synthesis of compounds for treatment of cardiovascular disorders and fibrotic disorders are also disclosed.

Aminodicarboxylic acid derivatives having pharmaceutical properties

The present invention relates to the use of compounds of the formula (I) and to their salts and stereoisomers, for the preparation of medicaments for the treatment of cardiovascular disorders.

Dicarboxylic acid derivatives with pharmaceutical properties

The present invention relates to a process for preparing optionally substituted arylsulphonic anhydrides of the general formula (I) 

Process for preparing optionally substituted arylsulphonic anhydrides

The invention relates to substituted 2-Phenyl-3(2H)-Pyridazinones, to a method for the production thereof, and to their use as medicaments for the prophylaxis and/or treatment of diseases in humans and/or animals.

Substituted 2-phenyl-3(2h)-pyridazinones

The invention relates to compounds of formula (I) as well as the salts and stereoisomers thereof

Derivatives of dicarboxylic acid having pharmaceutical properties

The invention relates to new imidazotriazines, processes for their preparation, and their use for the production of medicaments for the treatment and/or prophylaxis of neurodegenerative disorders, in particular Parkinson's disease.

Imidazotriazines for use as phosphodiesterase inhibitors

The present invention relates to pyrrolo[2.1-a]dihydroisoquinolines which are inhibitors of phosphodiesterase 10a and can be used for combating cancer.

Pyrrolo (2.1a)dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors

The invention relates to novel aryl and heteroaryl sulfonates of formula (Ia) and to methods for producing them and to novel aryl and heteroaryl sulfonates of formula (I) for treating and/or preventing diseases, especially for treating pain and neurodegenerative diseases, A representing (C-C)-aryl or 5-10-membered heteroaryl, D representing (C-C)-arylene or 5-10-membered heteroarylene, Rrepresenting (C-C)-alkyl, (C-C)-alkyl, the carbon chain being interrupted by one or two heteroatoms or groups chosen from the following group: &#x2014;O&#x2014;, &#x2014;S&#x2014;, &#x2014;SO&#x2014; and &#x2014;SO&#x2014;, (C-C)-alkenyl or (C-C)-alkinyl, in formula (Ia); and Rrepresenting (C-C)-alkyl, (C-C)-alkyl, the carbon chain being interrupted by one or two heteroatoms or groups chosen from the following group: &#x2014;O&#x2014;, &#x2014;S&#x2014;,&#x2014;SO&#x2014; and &#x2014;SO&#x2014;, (C-C)-alkenyl or (C-C)-alkinyl.

Aryl and heteroaryl sulfonates

The present invention relates to the compounds of the general formula (I)and their salts and stereoisomers for the production of medicaments for the treatment of cardiovascular disorders.

The invention relates to a process and intermediates for the preparation of enantiomerically pure cycloalkanoindolecarboxylic acids and azaindolecarboxylic acids and pyrimido&lsqb;1,2a&rsqb;indolecarboxylic acids and their activated derivatives, characterized in that the tolyl acetic acid is first esterified with a chiral alcohol, then diastereoselective substitution at &agr;-carbon atoms is carried out and this product is halogenated in the tolyl group and then reacted with appropriate cycloalkanoindoles, cycloalkanoazaindoles or pyrimido&lsqb;1,2a&rsqb;indoles. It is possible by this method to prepare specifically, in high purity, the enantiomerically pure carboxylic acids which are intermediates for valuable medicaments.

Process for the preparation of enantiomerically pure cycloalkano-indol -and azaindol -and pyrimido &lsqb;1,2A&rsqb;indolcarbocyclic acids and their activated derivatives

The invention relates to novel phenoxyphenyl alkanesulphonates, processes for their preparation, their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment of states of pain and neurodegenerative disorders.

Phenoxyphenyl alkanesulphonates

Substituted tetrahydro-naphthalenes and analogous compounds are prepared by reducing or condensing appropriate functional substituents in substituted tetrahydro-naphthalenes and analogous compounds by customary methods and converting functional groups in this manner into the desired groups. The compounds according to the invention are suitable for use as active compounds in pharmaceuticals, in particular in pharmaceuticals for treating arteriosclerosis and also dyslipidaemias.

Substituted tetrahydronaphthaline and analogous compounds

The cycloalkano-pyridines are prepared by reacting corresponding cycloalkano-pyridine-aldehydes with suitable organometallic compounds or Wittig or Grignard reagents or reacting compounds of the cycloalkano-pyridine alcohols type with suitable bromine compounds, and optionally varying the functional groups accordingly. The cycloalkanopyridines are suitable as active compounds in medicaments, in particular in medicaments for the treatment of hypertipoproteinaemia and arteriosclerosis.

Cycloalkano-pyridines

The cycloalkano-pyridines are prepared by reacting corresponding cycloalkano-pyridine-aldehydes with suitable organometallic compounds or Wittig or Grignard reagents or reacting compounds of the cycloalkano-pyridine alcohols type with suitable bromine compounds, and optionally varying the functional groups accordingly. The, cycloalkanopyridines are suitable as active compounds in medicaments, in particular in medicaments for the treatment of hyperlipoproteinaemia and arteriosclerosis.

Growing community of inventors

Wuppertal, Germany

Paul Naab